Intellia Therapeutics (Intellia Therapeutics) Total Liabilities : $250.81 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Total Liabilities?

Intellia Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $250.81 Mil.

Intellia Therapeutics's quarterly Total Liabilities declined from Jun. 2023 ($218.35 Mil) to Sep. 2023 ($205.94 Mil) but then increased from Sep. 2023 ($205.94 Mil) to Dec. 2023 ($250.81 Mil).

Intellia Therapeutics's annual Total Liabilities increased from Dec. 2021 ($254.22 Mil) to Dec. 2022 ($284.53 Mil) but then declined from Dec. 2022 ($284.53 Mil) to Dec. 2023 ($250.81 Mil).

Intellia Therapeutics Total Liabilities Historical Data

The historical data trend for Intellia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Total Liabilities Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

64.40

149.25

254.22

284.53

250.81

Intellia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															284.53	227.05	218.35	205.94	250.81

Intellia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intellia Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	115.208	+	(96.747	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	38.853	+	0)
	=	250.81

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1300.977	-	1050.169
	=	250.81

Intellia Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	115.208	+	(96.747	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	38.853	+	0)
	=	250.81

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1300.977	-	1050.169
	=	250.81

Intellia Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (Intellia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Executives

Laura Sepp-lorenzino	officer: EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta	officer: EVP, General Counsel	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks	officer: EVP, Chief Business Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark	officer: EVP, Chief Technical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl	officer: EVP, Chief Medical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard	officer: See Remarks	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard	director, officer: President and CEO	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera	officer: EVP, General Counsel	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier	officer: EVP, Chief Operating Officer	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139